[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Acrivon Therapeutics insiders reported routine post-vesting share dispositions on 08/14/2025. The Form 4 shows that restricted stock units were treated by the issuer to cover mandatory tax withholding: 59,766 shares were withheld at an effective price of $1.39, recorded as a disposition. After that transaction, Peter Blume-Jensen is shown as beneficially owning 2,146,345 shares (direct) and 315,196 shares (indirect) attributable to spouse holdings. A separate small disposition of 490 shares at $1.39 is reported as indirect ownership. Both Dr. Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations) are listed as reporting persons and each signed via attorney-in-fact on 08/18/2025.

Positive

• Mandatory tax-withholding is disclosed, showing RSU vesting mechanics applied transparently (59,766 shares withheld at $1.39).
• Spousal ownership and disclaimers are clearly stated, with footnotes explaining indirect holdings and pecuniary interest.
• Filing is signed and dated (08/18/2025) by attorney-in-fact for both reporting persons, meeting procedural requirements.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider tax-withholding after RSU vesting; no new market-impacting purchases or unusual sales reported.

The Form 4 discloses share withholding to satisfy tax obligations following RSU vesting and small dispositions at $1.39 per share on 08/14/2025. The transactions reduce reported share counts but reflect tax-related mechanics rather than directional trading intent. Reported beneficial ownership levels remain in the low millions for the CEO, with additional indirect holdings through a spouse. This filing is informational and likely not material to valuation absent other context.

Corporate Governance Expert

TL;DR: Disclosure is complete for the reported transactions and includes required spousal disclaimers; signatures are present.

The Form 4 includes explanatory footnotes clarifying that shares were withheld for tax withholding and identifies spousal relationships with appropriate disclaimers of beneficial ownership except for pecuniary interest. Both reporting persons are officers/directors and the filing is signed by an attorney-in-fact, dated 08/18/2025, meeting procedural requirements for Section 16 reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		F(1)		59,766	D	$1.39	2,146,345	D(2)
Common Stock	08/14/2025		F(1)		490	D	$1.39	315,196	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	08/18/2025
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ACRV insiders report on 08/14/2025?

The Form 4 reports withholding of 59,766 shares and a disposition of 490 shares, each at $1.39, on 08/14/2025.

Who filed the Form 4 for Acrivon Therapeutics (ACRV)?

The reporting persons are Dr. Peter Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations); both filings are signed by an attorney-in-fact on 08/18/2025.

Why were shares withheld in the reported transactions?

Footnote 1 states shares were withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

How many shares does the CEO beneficially own after the reported transaction?

After the reported transactions the Form 4 shows 2,146,345 shares beneficially owned directly by Dr. Peter Blume-Jensen and 315,196 shares listed as indirect holdings related to his spouse.

Are there any indications of major sales or purchases in this Form 4?

No; the reported dispositions are routine tax-withholding and a small 490-share disposition, not large market-moving trades.